Search Results
Apr 30, 2026, 06:45 ET Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
milestone was the U.S. FDA approval of Foundayo—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s. We also delivered pipeline progress across all four therapeutic
More news about: Eli Lilly and Company
Apr 29, 2026, 20:10 ET Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
Apr 29, 2026, 20:10 ET 歌禮將攜多個項目數據亮相美國糖尿病協會2026年度科學會議
日期/時間：2026年6月7日，周日，美國中部時間 (CT) 下午12:30標題：GLP-1口服小分子ASC30在肥胖受試者的13周美國II期研究顯示經安慰劑校正後的體重下降7.7%，且胃腸道耐受性更佳 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants
More news about: 歌禮製藥有限公司
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
for GLP-1 therapeutics due to tolerability or other reasons. The company has developed a series of potent agonists of the amylin and calcitonin receptors, which could play an important role as both single agents or in combination with GLP-1 or dual GLP-1/GIP agonists.During
More news about: Viking Therapeutics, Inc.
Apr 29, 2026, 12:26 ET Ember LifeSciences introduces Ember Cube 2, earns 'Best of the Best' Red Dot Design Award
medicines to increasing risk. Moreover, the number of medicines requiring temperature-controlled logistics — including injectable biosimilars and GLP-1 inhibitors — continues to increase each year.
More news about: Ember LifeSciences
Apr 28, 2026, 16:05 ET Cirius Therapeutics Announces Gestational Diabetes Initiative
beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous adipose tissue includes dramatic
More news about: Cirius Therapeutics
Apr 28, 2026, 12:46 ET Anvisa aprova Rybelsus®, semaglutida oral da Novo Nordisk, para redução do risco cardiovascular em adultos
Rybelsus® (semaglutida oral) é a primeira e única medicação oral da classe agonista do receptor de GLP-1 aprovado pela Anvisa (Agência Nacional de Vigilância Sanitária) no Brasil e agora passa a ser indicado para reduzir o risco de doenças no coração e eventos cardiovasculares,
More news about: Novo Nordisk
Apr 28, 2026, 12:27 ET FuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment
"What's exciting about Foundayo is that it builds on what we already know works with GLP-1s, but removes the factor of needles, which is one of the biggest barriers to GLP-1 care for patients," said Dr. Michael Snyder, in-house obesity specialist at FuturHealth. "The key is
More news about: FuturHealth
Apr 28, 2026, 08:26 ET Penn Dental Medicine Study Investigates Plant-encapsulated Delivery Platform for Oral Delivery of GLP-1 Drugs
notes. The current GLP-1 drugs have two artificial amino acids incorporated in them to make them last longer in the body."The GI problems are most likely associated with synthetic GLPs," Daniell says, "because such complaints were not frequent with natural GLP-1RAs like lixisenatide
More news about: PENN DENTAL MEDICINE
Apr 27, 2026, 10:15 ET mHealth Market Size to Hit USD 370.7 billion, Globally, by 2032 at 18.0% CAGR: Allied Market Research
diabetes-focused mHealth solutions globally.September 2024: Mobile Health Consumer, Inc. launched two new programs to address growing demand for GLP-1 medications while supporting lasting lifestyle interventions reflecting the emerging integration of weight management therapeutics with mobile health
More news about: Allied Market Research
Apr 27, 2026, 09:15 ET 5WPR and Haute MD Release the 2026 Medical Aesthetics AI Visibility Index, Ranking the Top 25 Brands Dominating AI Search in a $22 Billion Category
First joint research report measures how Botox, Juvéderm, CoolSculpting, SkinCeuticals, and Morpheus8 are winning AI citation share as GLP-1 demand and the collapse of social-media referral reshape the medical aesthetics marketNEW YORK,
More news about: 5W Public Relations
Apr 27, 2026, 08:45 ET Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
design approaches have the potential to move peptide discovery beyond the traditional evolutionary sampling that shaped therapeutics such as GLP-1 agonists, toward de novo design of peptide drugs against novel targets.The company recently announced
More news about: Decoy Therapeutics, Inc
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
diagnostics; and driving the emergence of RHB-102 (Bekinda) as a potential answer to GLP-1/GIP-related nausea, vomiting and diarrhea - one of the biggest growth restrictors in the $100 billion GLP-1 market."In summarizing 2025, Mr. Ben-Asher added: "We have unlocked significant
More news about: RedHill Biopharma Ltd.
Apr 26, 2026, 20:10 ET Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of
More news about: Ascletis Pharma Inc.
Apr 26, 2026, 20:10 ET 歌禮宣布口服小分子GLP-1R激動劑ASC30治療糖尿病的美國II期研究完成入組
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/glp-1rasc30ii-302753630.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Apr 24, 2026, 22:47 ET Menu-Order-AI Surpasses 110,000 Downloads as It Targets the Biggest Gap in the GLP-1 Era: What to Order
Menu-Order-AI, "The GLP-1 dining companion!", has surpassed 110,000 downloads in just four and a half months since launch, signaling rapid demand for real-time dining decisions in the rapidly evolving, industry-altering GLP-1 landscape.
More news about: MENU - ORDER AI
Apr 24, 2026, 22:30 ET Menu-Order-AI Surpasses 110,000 Downloads as It Targets the Biggest Gap in the GLP-1 Era: What to Order
Menu-Order-AI, "The GLP-1 dining companion!", has surpassed 110,000 downloads in just four and a half months since launch, signaling rapid demand for real-time dining decisions in the rapidly evolving, industry-altering GLP-1 landscape. As GLP-1 adoption accelerates,
More news about: MENU - ORDER AI
Apr 24, 2026, 13:00 ET Betterness Closes $2.5m Seed Round and Launches Bett-i, the First Fully Autonomous Voice-First Life-Coaching System for Health and Performance
biomarkers and recovery protocols onto your panel. If you're planning a pregnancy, it pivots to preconception optimization. If you're on a GLP-1, it watches the specific markers that matter.HIPAA-grade governance and trust. Consent-gated access, full audit trail, end-to-end
More news about: Betterness, Inc.
Apr 23, 2026, 11:05 ET 10 Ways Parents Can Treat Themselves with Tax-free Flexible Spending Account (FSA) and Health Savings Account (HSA) Funds at FSA Store® and HSA Store®
this can be difficult to achieve for busy parents. Fortunately, FSA Store® and HSA Store® collaborate with leading providers of GLP-1
More news about: Health-E Commerce
Apr 23, 2026, 10:40 ET /C O R R E C T I O N -- Sleep Corner/
that.By combining at-home diagnostics, physician-guided telehealth, treatment pathways (including CPAP, oral appliance therapy, and GLP-1), clinically proven supplementation, CBT-i, and dedicated care coordination—now supported by insights from Metabolic Code's personalized analysis
More news about: Sleep Corner
Apr 23, 2026, 09:00 ET Pathways to wellbeing: Miraval Berkshires Resort & Spa leads the field in intentional travel with nine experiences designed to enrich, reset and connect
cultivate resilience and enduring balance.6) Brain food: mindful eatingIn an era dominated by the quick-fix culture of GLP-1 medications, Miraval Berkshires presents an evolved alternative to conventional weight-loss retreats or bootcamps. A sanctuary for metabolic
More news about: Miraval Berkshires Resort & Spa
Apr 23, 2026, 06:00 ET West Reports First-Quarter 2026 Results
expectations. Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues. The better-than-expected performance can be attributed to continued market demand and the team's outstanding efforts in ramping
More news about: West Pharmaceutical Services, Inc.
Apr 22, 2026, 16:35 ET Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
Apr 22, 2026, 11:57 ET Global Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation
cloud-native platforms is improving efficiency and data accuracyRegulatory Compliance Pressure: Standards such as FDA 21 CFR Part 11, GLP/GMP, and HIPAA are driving demand for secure and auditable ELN systemsGlobal Collaboration Needs: Cloud ELNs enable real-time data sharing
More news about: Future Market Insights
Apr 22, 2026, 11:14 ET Mô hình chăm sóc kết hợp của NOVI Health thu hẹp khoảng cách giữa thử nghiệm lâm sàng và kết quả thực tế khi sử dụng GLP-1
thụ thể GLP-1 với huấn luyện kỹ thuật số qua ứng dụng và hỗ trợ lối sống cá nhân hóa. Kết quả nổi bật: mức giảm cân trung bình ước tính ~12,7% sau 12 tháng và ~14,7% sau 18 tháng, tương đương với kết quả từ các thử nghiệm lâm sàng và cao hơn đáng kể so với kết quả GLP-1 thông
More news about: NOVI Health